Techcyte, a leader in AI-powered digital pathology, today announced the reorganization of its Board of Directors to support the company’s continued growth and mission to develop the leading digital pathology platform.

Ralph Yarro, a Techcyte founder, will continue his service on the board as chairman. Continuing directors also include Karine Sellam, Vice President and Global Head of Business Development at Zoetis; Ben Cahoon, CEO of Techcyte; and Dr. Mohamed Salama, CMO at Sonic Healthcare USA and whose early work in blood cell classification helped inspire the company’s founding.

Joining the board as new directors are Mark McNabb, Head of the Private Capital Group at the Van Tuyl Family Office, and Jim Rogers, CEO of Mayo Clinic Digital Pathology.

Jim Rogers leads Mayo Clinic Digital Pathology, which focuses on scaling digital pathology through advancements in scanning, storage, artificial intelligence, and algorithm development. He brings extensive experience in healthcare innovation, commercialization, business development, and institutional strategy.

Commenting on his appointment, Rogers said, “Pathology is entering an important period of transformation. I look forward to working together to bring digital pathology innovation into broader use.”

Mark McNabb leads the Private Capital Group at the Van Tuyl Family Office and brings more than three decades of experience guiding complex organizations through growth and transformation. His career includes senior leadership roles at Nissan, Mercedes-Benz USA, General Motors, Maserati, and Volkswagen Group of America, as well as serving as the founding CEO of Electrify America.

On joining Techcyte’s board, McNabb said, “Techcyte has a significant opportunity ahead. I look forward to helping the company build the operational foundation needed to pursue that opportunity at scale.”

“Techcyte was founded on the belief that combining the knowledge of laboratory professionals and pathologists with advanced technology could meaningfully change how pathology is delivered,” said Ben Cahoon, CEO of Techcyte. “Each member of this board brings a perspective that is important to advancing that mission. Together, they provide the clinical, technical, commercial, and operational experience needed to help Techcyte rapidly grow to reach profitability and deliver lasting value to laboratories and the people they serve.”

The reorganized board will help Techcyte navigate the opportunities and decisions that come with expanding its platform, deepening strategic partnerships, and bringing AI-powered digital pathology to more laboratories.